Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to determine in vitro effects on mitochondrial function of selected chemical agents in human cells, and assess the capability of a cell-permeable succinate prodrug to attenuate toxic effects The project aims at repurposing this recent pharmaceutical discovery, currently being developed for treatment of toxic exposure, for an expanded indication to treat chemically induced mitochondrial toxicity.


Clinical Trial Description

The study duration per subject will be approximately 15 minutes to complete the one time blood collection. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03597438
Study type Observational
Source Children's Hospital of Philadelphia
Contact
Status Completed
Phase
Start date May 7, 2018
Completion date February 22, 2024

See also
  Status Clinical Trial Phase
Completed NCT03727646 - Nicotinamide Riboside in LVAD Recipients Early Phase 1
Recruiting NCT05858463 - High Intensity Interval Training and Muscle Adaptations During PR N/A
Recruiting NCT06167135 - Polycystic Ovary Syndrome, Mitochondrial Dysfunction, Obesity, Insulin Resistance Infertility (POMODORI) Cohort
Withdrawn NCT04756674 - The Impact of Covid-19 on Skeletal Muscle
Not yet recruiting NCT06191965 - MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction Phase 2/Phase 3
Completed NCT04193566 - Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes Phase 4
Completed NCT03052595 - Multiple Sclerosis: The Role of Mitochondrial Dysfunction in IR Resistance
Completed NCT03251144 - Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) Phase 1/Phase 2
Completed NCT03119350 - Mitochondrial Energy Metabolism in Obese Women N/A